Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex Ultravist imaging agent will be launched in July; approved May 10, two years after advisory committee.

Executive Summary

BERLEX ULTRAVIST CONTRAST AGENT WILL BE AVAILABLE IN JULY, the company announced May 12. The iodinated, non-ionic contrast agent iopromide for x-ray imaging and computed tomography scanning (NDA 20-220) was approved by FDA on May 10, almost two years after FDA's Medical Imaging Drugs Advisory Committee unanimously recommended approval for eight indications ("The Pink Sheet" May 31, 1993, T&G-2).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel